Product image of Myrelez (Lanreotide Acetate) supplied by GNH India

Myrelez

Active Ingredient:
Lanreotide Acetate
Origin:
EU

Myrelez (Lanreotide Acetate)

Lanreotide Acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile solution for subcutaneous injection, typically supplied in a prefilled syringe. It is used to treat acromegaly by lowering excess growth hormone and to provide symptomatic control of gastroenteropancreatic neuroendocrine tumors in adult patients.

GNH India supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance and patient safety across multiple global markets.

Manufacturer / TM Owner

Amdipharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Myrelez, a somatostatin analog used in hormone‑secreting tumor management, is indicated for:
  • Acromegaly: reduces excess growth hormone levels and improves associated clinical signs.
  • Gastroenteropancreatic neuroendocrine tumors (GEP‑NET): provides symptomatic control of hormone‑related flushing, diarrhoea and abdominal pain.
  • Carcinoid syndrome: alleviates flushing, diarrhoea and abdominal cramping caused by peptide hormone secretion in neuroendocrine tumors.
  • Hormone‑secreting pituitary adenoma: helps lower hormone output and may reduce tumor size in selected patients.

How It Works

  • Lanreotide acetate binds with high affinity to somatostatin receptor subtypes 2 and 5 on target cells. This interaction inhibits adenylate cyclase activity, decreasing cyclic AMP formation and suppressing the secretion of growth hormone, insulin, glucagon and other peptide hormones, thereby reducing hormone‑driven disease activity.

Side Effects

Adverse reactions reported with Myrelez are categorized by frequency.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Diarrhoea: increased frequency of loose stools.
  • Nausea: transient feeling of sickness.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Gallstone formation: development of biliary calculi.
  • Acute pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
  • Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.

Precautions & Warnings

Before initiating Myrelez, consider the following precautions.

  • Monitor blood glucose: assess for hyperglycaemia, especially in diabetic patients.
  • Evaluate gallbladder status: patients with gallstones may require monitoring.
  • Screen for pancreatitis: discontinue if signs of acute pancreatitis appear.
  • Assess cardiac function: use cautiously in patients with known arrhythmias.
  • Pregnancy and lactation: prescribe only if potential benefit justifies the risk to the fetus or infant.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Myrelez may interact with other medicines; notable interactions include:

Major Interactions (Avoid)

  • Concomitant use with other somatostatin analogs: may increase risk of hormonal suppression.
  • Cyclosporine: lanreotide can raise cyclosporine concentrations, increasing nephrotoxicity risk.
  • Insulin or oral hypoglycaemic agents: may alter glucose control, requiring dose adjustments.

Moderate Interactions (Monitor Closely)

  • Octreotide: additive somatostatin effects may enhance adverse events.
  • Dopamine agonists (e.g., cabergoline): may affect endocrine balance and require monitoring.

Frequently Asked Questions

Myrelez contains lanreotide acetate, a somatostatin analog indicated for the treatment of acromegaly and for symptomatic control of gastroenteropancreatic neuroendocrine tumors, including carcinoid syndrome. It helps lower excess hormone levels that drive disease symptoms.

Lanreotide acetate binds selectively to somatostatin receptor subtypes 2 and 5 on endocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon and other peptide hormones, thereby mitigating hormone‑driven disease activity.

The dosing regimen for Myrelez is individualized and determined by the prescribing healthcare professional based on the patient’s condition, response and clinical guidelines. Specific dose amounts and intervals are not disclosed here and should be obtained from the treating physician.

Safety data for Myrelez during pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician in consultation with the patient.

To order Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to Myrelez is octreotide, another somatostatin analog. Both agents suppress hormone secretion, but lanreotide has a longer dosing interval (often every 4 weeks) compared with octreotide’s more frequent dosing, which may improve convenience for some patients.

Myrelez should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Myrelez is administered by subcutaneous injection, usually using a prefilled syringe. The injection is given into the abdominal wall or thigh, following the technique and site‑rotation guidelines provided by the prescribing clinician.

Serious risks include the development of gallstones, acute pancreatitis, and severe allergic reactions such as anaphylaxis. Patients should be educated to seek immediate medical attention if they experience intense abdominal pain, jaundice, swelling, rash, or breathing difficulties.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is advised for individuals with uncontrolled diabetes, active gallbladder disease, severe cardiac arrhythmias, or those who are pregnant or breastfeeding without a clear benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT